The document summarizes the history and activities of Aeterna Zentaris, a biopharmaceutical company. It discusses:
- The founding of Aeterna Laboratories in 1990 to develop cancer medicines.
- The acquisition of Zentaris AG in 2002, which expanded their oncology and endocrinology product portfolio.
- The 2004 merger with Zentaris AG and name change to Aeterna Zentaris Inc., focusing their activities in oncology, endocrinology, and fertility.
- Their marketed products including Cetrotide for fertility treatment, and clinical trials of other oncology drugs.
The document summarizes the history and activities of Aeterna Zentaris, a biopharmaceutical company founded in 1990 as Aeterna Laboratories. It discusses the company's focus on oncology research and key milestones such as acquisitions, clinical trials of products like Perifosine, and partnership agreements. The company has experienced both successes like the approval and marketing of Cetrotide and challenges like the discontinuation of clinical trials for some oncology products. It currently has a pipeline of potential therapies and diagnostic tests in oncology and endocrinology.
Medgenics presented an overview of their Biopump technology for sustained protein delivery and their lead product candidates. The Biopump uses skin tissue to continuously produce and deliver therapeutic proteins from a patient's own skin for 6-36 months to treat chronic diseases like anemia, hepatitis, and hemophilia. Clinical trials have demonstrated sustained protein levels and disease treatment for this duration from a single treatment. Medgenics' experienced management team is advancing lead programs in Phase I/II trials while pursuing strategic partnerships for their disruptive platform technology addressing large markets exceeding $130 billion annually.
The document summarizes a sales meeting focused on taxane-related products, noting that taxanes require significant engineering for their formulation and that drugs like docetaxel and vinorelbine will become off-patent in the near future, presenting an opportunity. It provides details on companies developing lipid-soluble taxane products and clinical trials underway, and highlights a recent investigational new drug application filed for a novel liposomal docetaxel delivery system.
There are several methods for delivering insulin to diabetics, including syringes, insulin pens, insulin pumps, and inhaled insulin. Insulin pumps mimic the pancreas by providing a continuous basal insulin dose throughout the day and additional bolus doses when meals are eaten. The number of diabetic patients in India is increasing and insulin delivery systems represent a growing market opportunity in the country.
The document discusses trends in the Australian pharmaceutical industry. It notes that the industry is worth $22 billion annually and is a top exporter. Key trends include the industry's reliance on government subsidies through the Pharmaceutical Benefits Scheme, higher life expectancies increasing drug consumption, and the growth of generics. The industry faces pressures from the strong Australian dollar and increased automation. Pfizer is a major player with manufacturing plants in Sydney, Melbourne and Perth and partnerships with research organizations. The strategies discussed to address challenges include focusing on innovation, manufacturing technologies, and collaborating between industry and researchers.
MEDICA MEDIA FORUM
„ePatient/Health 2.0: Schlüsselfaktor für neue, zukunftsfähige Geschäftsmodelle der Life Sciences Industrie“
Impulsreferat von Matthias Wartenberg, Executive Director Advisory Service LifeScience, Ernst & Young, Eschborn
The pre-conference workshop will provide an interactive forum for attendees to engage with leaders on regulatory challenges surrounding biosimilars in the US and EU. The workshop will compare the EU's experience in introducing biosimilars, lessons learned, and new developments, with the recent introduction of biosimilar legislation in the US. Attendees will have the opportunity to participate in group discussions and Q&A sessions on these topics led by experts Dr. Angela Thomas of the MHRA and Dr. Anita O'Connor. The small group setting is designed to foster maximum interaction between leaders and delegates.
The document summarizes the history and activities of Aeterna Zentaris, a biopharmaceutical company founded in 1990 as Aeterna Laboratories. It discusses the company's focus on oncology research and key milestones such as acquisitions, clinical trials of products like Perifosine, and partnership agreements. The company has experienced both successes like the approval and marketing of Cetrotide and challenges like the discontinuation of clinical trials for some oncology products. It currently has a pipeline of potential therapies and diagnostic tests in oncology and endocrinology.
Medgenics presented an overview of their Biopump technology for sustained protein delivery and their lead product candidates. The Biopump uses skin tissue to continuously produce and deliver therapeutic proteins from a patient's own skin for 6-36 months to treat chronic diseases like anemia, hepatitis, and hemophilia. Clinical trials have demonstrated sustained protein levels and disease treatment for this duration from a single treatment. Medgenics' experienced management team is advancing lead programs in Phase I/II trials while pursuing strategic partnerships for their disruptive platform technology addressing large markets exceeding $130 billion annually.
The document summarizes a sales meeting focused on taxane-related products, noting that taxanes require significant engineering for their formulation and that drugs like docetaxel and vinorelbine will become off-patent in the near future, presenting an opportunity. It provides details on companies developing lipid-soluble taxane products and clinical trials underway, and highlights a recent investigational new drug application filed for a novel liposomal docetaxel delivery system.
There are several methods for delivering insulin to diabetics, including syringes, insulin pens, insulin pumps, and inhaled insulin. Insulin pumps mimic the pancreas by providing a continuous basal insulin dose throughout the day and additional bolus doses when meals are eaten. The number of diabetic patients in India is increasing and insulin delivery systems represent a growing market opportunity in the country.
The document discusses trends in the Australian pharmaceutical industry. It notes that the industry is worth $22 billion annually and is a top exporter. Key trends include the industry's reliance on government subsidies through the Pharmaceutical Benefits Scheme, higher life expectancies increasing drug consumption, and the growth of generics. The industry faces pressures from the strong Australian dollar and increased automation. Pfizer is a major player with manufacturing plants in Sydney, Melbourne and Perth and partnerships with research organizations. The strategies discussed to address challenges include focusing on innovation, manufacturing technologies, and collaborating between industry and researchers.
MEDICA MEDIA FORUM
„ePatient/Health 2.0: Schlüsselfaktor für neue, zukunftsfähige Geschäftsmodelle der Life Sciences Industrie“
Impulsreferat von Matthias Wartenberg, Executive Director Advisory Service LifeScience, Ernst & Young, Eschborn
The pre-conference workshop will provide an interactive forum for attendees to engage with leaders on regulatory challenges surrounding biosimilars in the US and EU. The workshop will compare the EU's experience in introducing biosimilars, lessons learned, and new developments, with the recent introduction of biosimilar legislation in the US. Attendees will have the opportunity to participate in group discussions and Q&A sessions on these topics led by experts Dr. Angela Thomas of the MHRA and Dr. Anita O'Connor. The small group setting is designed to foster maximum interaction between leaders and delegates.
The survey examined how clinical research outsourcing relationships between sponsors and service providers are expected to change between 2010-2014. 285 respondents participated, including 109 sponsors and 174 service providers. For sponsors, the top changes made/planned to improve efficiency included better measurement of provider performance, increased use of preferred providerships, and better methods for provider selection. Respondents were asked about drivers of change and how planned changes may impact outsourcing strategies and relationships over this time period.
Biopharmaceuticals are an essential therapeutic option accounting for a substantial part of the global therapeutic market. With the patents of many blockbuster drugs coming to an end, an opportunity has arisen for the manufacture and approval of biosimilars. Visiongain\'s 9th Biosimilars Conference will look at the multiple facets of biosimilars, ranging from the evolving regulatory landscape and challenges in clinical development, to the legal and economic aspects.
Mark Redmond has worked in various areas of innovation including genetically engineered vaccines, immunopharmaceuticals to control infection and disease, anti-inflammatory drugs, wound care products, diabetes diagnostics, and over 120 patented health technologies. He has designed manufacturing processes and plants, developed business strategies, international partnerships, and earned awards for his scientific and commercial achievements.
Biocon is India's leading biotech company founded in 1978 by Kiran Mazumdar Shaw. It focuses on developing biopharmaceuticals and was the first company in Asia and 16th globally in terms of revenue and market capitalization. Some key milestones include being the first company to produce human insulin using a Pichia expression system and becoming India's first billion dollar biotech company. Kiran Mazumdar Shaw overcame many hurdles in the early years to build Biocon into the successful company it is today through her determination and vision.
Proposal for cord blood banking and therapeutics business (roll up strategy ...ProteusVenturePartners
This document proposes building the leading international cryo-banking and stem cell therapeutics company through two phases. Phase I involves acquiring a market leading cord blood bank and rolling up smaller underperforming banks, aggressively marketing to drive revenues and expanding the tissue offering. Phase II brings regenerative medicine therapeutics to emerging markets, initially leveraging stored tissue and addressing unmet regional medical needs with proven therapies. Funding requirements and an exit strategy are also discussed.
Addison Whitney is a leading provider of clinical, communications, and commercialization solutions to the pharmaceutical and life sciences industry. It offers services such as trademark development, market research, visual branding including logo design, and brand strategy. Addison Whitney has a large client list of major pharmaceutical companies as well as emerging and medium-sized clients. It has developed trademarks and brand names for many pharmaceutical products and provided visual identity design for several drug brands.
This document discusses opportunities for research and innovation in Europe. It profiles Gitte Neubauer's career path, which began with an undergraduate degree in biochemistry in the UK and a PhD in proteomics from Imperial College London. It then describes her work at the European Molecular Biology Laboratory in Heidelberg, Germany, a top-ranked institute for molecular biology and genetics. The document next outlines Neubauer's transition to industry, where she founded Cellzome in 2000 to apply proteomics to drug discovery and built it into a successful biotech company through collaborations with pharmaceutical companies and venture capital funding. Finally, it notes that Cellzome employees have moved between academia and industry, and that while work-life balance is
This document outlines a 10 step marketing plan for Aforvir, an affordable antihistamine medication for children. The target market is physicians who treat allergies in children aged 6 months to 5 years. Aforvir will position itself as effective, affordable, and pleasant tasting compared to competitors. Key elements of the marketing plan include an emotional promotional campaign centered on reuniting children with pets, competitive pricing, and regular physician representative visits to promote Aforvir. The overall antihistamine market is valued at $116 million growing at 16% annually, and the goal is for Aforvir to gain a larger share through this marketing strategy.
Stem cells usa rm congress cord blood (boston, september 12, 2011)v.1ProteusVenturePartners
This document summarizes Gregory Bonfiglio's presentation on cord blood banking and therapeutics given at Stem Cells USA RM Congress in Boston, Massachusetts. The presentation covers the regenerative medicine market and cord blood market metrics, current cord blood banking practices and therapeutic applications, and therapies using cord blood that are in clinical development, with over 600 ongoing FDA clinical trials.
wyeth Download Documentation Credit Suisse Group Healthcare Conferencefinance12
This document is a presentation by Michael Kamarck from Wyeth discussing the company's manufacturing capabilities and strategies. It summarizes that Wyeth has a diversified business across pharmaceuticals, biotechnology, vaccines, and other areas. It has made over $3.5 billion in investments to support its biomanufacturing network and developed platform technologies to standardize processes. This allows production of multiple pipeline and commercial products using consistent materials and equipment. Wyeth has demonstrated the ability to increase yields and capacity for products like Enbrel and Prevnar through technological advances.
wyeth Credit Suisse Group Healthcare Conferencefinance12
This document provides an overview of Wyeth's business, including its diversification across scientific platforms, business platforms, and therapeutic approaches. It discusses Wyeth's core biotech/vaccine franchises that have high growth potential, such as Enbrel and Prevnar. The document also summarizes Wyeth's investments in biomanufacturing infrastructure and its leadership in biotech manufacturing and process development. Wyeth's standardized technology platforms are highlighted as helping to improve existing products and drive efficiencies.
Addison Whitney is a leading provider of clinical, communications, and commercialization solutions to the pharmaceutical and life sciences industry. They offer services such as trademark development, market research, branding, and strategy. Addison Whitney works with large pharmaceutical clients as well as many emerging and medium-sized clients. Their services include assigning trademarks, brand names, and nonproprietary names to drugs in development.
Pfizer at the 27th Annual J.P. Morgan Healthcare Conferencefinance5
This document summarizes a presentation given by Martin Mackay, President of PGRD, at a 2009 JP Morgan conference. The presentation outlines PGRD's strategic goals of aggressively advancing their clinical pipeline, prioritizing their portfolio, becoming a top biotherapeutics company, raising productivity, and pursuing external science. Key achievements from 2008 are noted, including global submissions, approvals, advancing compounds to Phase 3, and business development deals. PGRD's pipeline and goals to start 15-20 Phase 3 trials per year through 2009 are reviewed. Recent disease area focus and exit decisions are presented, as well as an overview of the new Biotherapeutics and Bioinnovation Center and its current pipeline.
Aesis corfù innovation summit oct 5 7 2015Paolo Lombardi
Aesis Therapeutics is a pharmaceutical company founded in 2013 focused on developing innovative oncology drugs. It has two drug candidates in development targeting two types of cancer with unmet needs: NAX035 for malignant mesothelioma and NAX014 for HER2-positive breast cancer. The company has raised €0.485 million in seed funding and plans to raise €2.42 million and €3.675 million in subsequent funding rounds to advance the drug candidates through Phase I clinical trials over three years. Successful completion of Phase I trials could result in a potential exit value of €10 million plus milestones.
BioEntrepreneurship: Intellectual Property: What Do Investors Look For?MaRS Discovery District
Strong patent protection is essential for a start-up biotechnology company and can be a valuable company asset. However, it is also expensive, with costs ranging from tens to hundreds of thousands of dollars over time. This session will focus on how to get the most out of your patent dollars.
This session presentation is available in audio format here: http://www.marsdd.com/bioent/dec4
Aah 422 Navc Past Present Future (Final))Robert Bowman
Abbott Laboratories was founded in 1888 by Dr. Wallace Abbott in Illinois with a goal of improving medical care. Today Abbott is a global leader in health care with over 68,000 employees worldwide. Abbott Animal Health has been a partner to veterinarians for over 25 years, providing leading products in areas like anesthesia, diagnostics, and nutrition. Looking to the future, Abbott Animal Health continues developing innovative veterinary solutions and leveraging the research expertise of Abbott Laboratories.
The Avoca Report Executive Summary: 2011 State of Clinical OutsourcingThe Avoca Group
1. There is an association between sponsor size and provider size, with large sponsors generally selecting large, full-service CROs and small sponsors generally selecting smaller, niche providers.
2. This association appears rational, as sponsors of all sizes report highest satisfaction rates when working with mid-sized providers, and small/mid-sized sponsors using large CROs for ≤25% of work are more satisfied than those using them for >25%.
3. While the association exists, satisfaction rates are remarkably similar across sponsor sizes, indicating the "best" provider depends more on individual project needs than sponsor size alone.
This document provides information about Amgen, a large biopharmaceutical company. It discusses Amgen's core products which treat conditions like anemia, arthritis, and cancer. The document outlines the mechanisms and potential side effects of each drug. It also identifies the main competitors for each of Amgen's core products. Key drugs discussed include Enbrel, Neulasta, and Nexavar. The document provides an overview of Amgen's business, products, and competitive landscape.
Novartis is a large pharmaceutical company headquartered in Switzerland that was formed in 1996 through the merger of Ciba-Geigy and Sandoz. Over the years, Novartis has expanded through acquisitions of companies like Alcon, Hexal, and Fougera to become a leader in pharmaceuticals, eye care, generics, and vaccines. The document provides details on Novartis' products, history, acquisitions, organizational structure, marketing issues, financial performance, and strategy for further growth.
The synthetic cell created by J. Craig Venter Institute researchers represents an important milestone, though the cell is not truly synthetic from scratch. While synthesizing the Mycoplasma mycoides genome was successful, the researchers encountered challenges in booting up the synthetic genome in a host cell. The creation of synthetic life raises philosophical and ethical issues and shows that life can be explained mechanistically. Additionally, Santhera Pharmaceutical's drug idebenone failed a second pivotal trial for Friedreich's ataxia, causing its stock price to plunge.
The survey examined how clinical research outsourcing relationships between sponsors and service providers are expected to change between 2010-2014. 285 respondents participated, including 109 sponsors and 174 service providers. For sponsors, the top changes made/planned to improve efficiency included better measurement of provider performance, increased use of preferred providerships, and better methods for provider selection. Respondents were asked about drivers of change and how planned changes may impact outsourcing strategies and relationships over this time period.
Biopharmaceuticals are an essential therapeutic option accounting for a substantial part of the global therapeutic market. With the patents of many blockbuster drugs coming to an end, an opportunity has arisen for the manufacture and approval of biosimilars. Visiongain\'s 9th Biosimilars Conference will look at the multiple facets of biosimilars, ranging from the evolving regulatory landscape and challenges in clinical development, to the legal and economic aspects.
Mark Redmond has worked in various areas of innovation including genetically engineered vaccines, immunopharmaceuticals to control infection and disease, anti-inflammatory drugs, wound care products, diabetes diagnostics, and over 120 patented health technologies. He has designed manufacturing processes and plants, developed business strategies, international partnerships, and earned awards for his scientific and commercial achievements.
Biocon is India's leading biotech company founded in 1978 by Kiran Mazumdar Shaw. It focuses on developing biopharmaceuticals and was the first company in Asia and 16th globally in terms of revenue and market capitalization. Some key milestones include being the first company to produce human insulin using a Pichia expression system and becoming India's first billion dollar biotech company. Kiran Mazumdar Shaw overcame many hurdles in the early years to build Biocon into the successful company it is today through her determination and vision.
Proposal for cord blood banking and therapeutics business (roll up strategy ...ProteusVenturePartners
This document proposes building the leading international cryo-banking and stem cell therapeutics company through two phases. Phase I involves acquiring a market leading cord blood bank and rolling up smaller underperforming banks, aggressively marketing to drive revenues and expanding the tissue offering. Phase II brings regenerative medicine therapeutics to emerging markets, initially leveraging stored tissue and addressing unmet regional medical needs with proven therapies. Funding requirements and an exit strategy are also discussed.
Addison Whitney is a leading provider of clinical, communications, and commercialization solutions to the pharmaceutical and life sciences industry. It offers services such as trademark development, market research, visual branding including logo design, and brand strategy. Addison Whitney has a large client list of major pharmaceutical companies as well as emerging and medium-sized clients. It has developed trademarks and brand names for many pharmaceutical products and provided visual identity design for several drug brands.
This document discusses opportunities for research and innovation in Europe. It profiles Gitte Neubauer's career path, which began with an undergraduate degree in biochemistry in the UK and a PhD in proteomics from Imperial College London. It then describes her work at the European Molecular Biology Laboratory in Heidelberg, Germany, a top-ranked institute for molecular biology and genetics. The document next outlines Neubauer's transition to industry, where she founded Cellzome in 2000 to apply proteomics to drug discovery and built it into a successful biotech company through collaborations with pharmaceutical companies and venture capital funding. Finally, it notes that Cellzome employees have moved between academia and industry, and that while work-life balance is
This document outlines a 10 step marketing plan for Aforvir, an affordable antihistamine medication for children. The target market is physicians who treat allergies in children aged 6 months to 5 years. Aforvir will position itself as effective, affordable, and pleasant tasting compared to competitors. Key elements of the marketing plan include an emotional promotional campaign centered on reuniting children with pets, competitive pricing, and regular physician representative visits to promote Aforvir. The overall antihistamine market is valued at $116 million growing at 16% annually, and the goal is for Aforvir to gain a larger share through this marketing strategy.
Stem cells usa rm congress cord blood (boston, september 12, 2011)v.1ProteusVenturePartners
This document summarizes Gregory Bonfiglio's presentation on cord blood banking and therapeutics given at Stem Cells USA RM Congress in Boston, Massachusetts. The presentation covers the regenerative medicine market and cord blood market metrics, current cord blood banking practices and therapeutic applications, and therapies using cord blood that are in clinical development, with over 600 ongoing FDA clinical trials.
wyeth Download Documentation Credit Suisse Group Healthcare Conferencefinance12
This document is a presentation by Michael Kamarck from Wyeth discussing the company's manufacturing capabilities and strategies. It summarizes that Wyeth has a diversified business across pharmaceuticals, biotechnology, vaccines, and other areas. It has made over $3.5 billion in investments to support its biomanufacturing network and developed platform technologies to standardize processes. This allows production of multiple pipeline and commercial products using consistent materials and equipment. Wyeth has demonstrated the ability to increase yields and capacity for products like Enbrel and Prevnar through technological advances.
wyeth Credit Suisse Group Healthcare Conferencefinance12
This document provides an overview of Wyeth's business, including its diversification across scientific platforms, business platforms, and therapeutic approaches. It discusses Wyeth's core biotech/vaccine franchises that have high growth potential, such as Enbrel and Prevnar. The document also summarizes Wyeth's investments in biomanufacturing infrastructure and its leadership in biotech manufacturing and process development. Wyeth's standardized technology platforms are highlighted as helping to improve existing products and drive efficiencies.
Addison Whitney is a leading provider of clinical, communications, and commercialization solutions to the pharmaceutical and life sciences industry. They offer services such as trademark development, market research, branding, and strategy. Addison Whitney works with large pharmaceutical clients as well as many emerging and medium-sized clients. Their services include assigning trademarks, brand names, and nonproprietary names to drugs in development.
Pfizer at the 27th Annual J.P. Morgan Healthcare Conferencefinance5
This document summarizes a presentation given by Martin Mackay, President of PGRD, at a 2009 JP Morgan conference. The presentation outlines PGRD's strategic goals of aggressively advancing their clinical pipeline, prioritizing their portfolio, becoming a top biotherapeutics company, raising productivity, and pursuing external science. Key achievements from 2008 are noted, including global submissions, approvals, advancing compounds to Phase 3, and business development deals. PGRD's pipeline and goals to start 15-20 Phase 3 trials per year through 2009 are reviewed. Recent disease area focus and exit decisions are presented, as well as an overview of the new Biotherapeutics and Bioinnovation Center and its current pipeline.
Aesis corfù innovation summit oct 5 7 2015Paolo Lombardi
Aesis Therapeutics is a pharmaceutical company founded in 2013 focused on developing innovative oncology drugs. It has two drug candidates in development targeting two types of cancer with unmet needs: NAX035 for malignant mesothelioma and NAX014 for HER2-positive breast cancer. The company has raised €0.485 million in seed funding and plans to raise €2.42 million and €3.675 million in subsequent funding rounds to advance the drug candidates through Phase I clinical trials over three years. Successful completion of Phase I trials could result in a potential exit value of €10 million plus milestones.
BioEntrepreneurship: Intellectual Property: What Do Investors Look For?MaRS Discovery District
Strong patent protection is essential for a start-up biotechnology company and can be a valuable company asset. However, it is also expensive, with costs ranging from tens to hundreds of thousands of dollars over time. This session will focus on how to get the most out of your patent dollars.
This session presentation is available in audio format here: http://www.marsdd.com/bioent/dec4
Aah 422 Navc Past Present Future (Final))Robert Bowman
Abbott Laboratories was founded in 1888 by Dr. Wallace Abbott in Illinois with a goal of improving medical care. Today Abbott is a global leader in health care with over 68,000 employees worldwide. Abbott Animal Health has been a partner to veterinarians for over 25 years, providing leading products in areas like anesthesia, diagnostics, and nutrition. Looking to the future, Abbott Animal Health continues developing innovative veterinary solutions and leveraging the research expertise of Abbott Laboratories.
The Avoca Report Executive Summary: 2011 State of Clinical OutsourcingThe Avoca Group
1. There is an association between sponsor size and provider size, with large sponsors generally selecting large, full-service CROs and small sponsors generally selecting smaller, niche providers.
2. This association appears rational, as sponsors of all sizes report highest satisfaction rates when working with mid-sized providers, and small/mid-sized sponsors using large CROs for ≤25% of work are more satisfied than those using them for >25%.
3. While the association exists, satisfaction rates are remarkably similar across sponsor sizes, indicating the "best" provider depends more on individual project needs than sponsor size alone.
This document provides information about Amgen, a large biopharmaceutical company. It discusses Amgen's core products which treat conditions like anemia, arthritis, and cancer. The document outlines the mechanisms and potential side effects of each drug. It also identifies the main competitors for each of Amgen's core products. Key drugs discussed include Enbrel, Neulasta, and Nexavar. The document provides an overview of Amgen's business, products, and competitive landscape.
Novartis is a large pharmaceutical company headquartered in Switzerland that was formed in 1996 through the merger of Ciba-Geigy and Sandoz. Over the years, Novartis has expanded through acquisitions of companies like Alcon, Hexal, and Fougera to become a leader in pharmaceuticals, eye care, generics, and vaccines. The document provides details on Novartis' products, history, acquisitions, organizational structure, marketing issues, financial performance, and strategy for further growth.
The synthetic cell created by J. Craig Venter Institute researchers represents an important milestone, though the cell is not truly synthetic from scratch. While synthesizing the Mycoplasma mycoides genome was successful, the researchers encountered challenges in booting up the synthetic genome in a host cell. The creation of synthetic life raises philosophical and ethical issues and shows that life can be explained mechanistically. Additionally, Santhera Pharmaceutical's drug idebenone failed a second pivotal trial for Friedreich's ataxia, causing its stock price to plunge.
4. 90/09/12: creation of Aeterna Laboratories by Eric and Luc Dupont
Aim: developing a medicine against cancer
Financial need: creation of Atrium Biotechnologies
Commercial division: cosmetics and nutritional supplement
Commercial earnings reinvest
in cancer R&D
Paul Burroughs, Communication
Director, Aeterna Zentaris Inc.
5. Cancerous cell
Black/Common Spiny Dog Fish
Fractions of cartilage: anti-angiogenesis power
Anti-collagenase activities: MMP inhibitors
Problem: quality of the powder composition
•Adequate extraction of the anti-angiogenic molecules
•Preservation of biological activities during extraction and storage
Shark cartilage extracts as anti-angiogenic agents: smart drinks or bitter pills? D. Gingras, A. Renaud, N.
Mousseau, R. B´eliveau, Cancer and Metastasis Reviews 19: 83–86, 2000.
6. New entity
•Water-soluble extract
•Concentrated in biologically-relevant molecules
Effect of Æ-941 on embryonic neovascularization.
Chick embryo
Shark cartilage extracts as anti-angiogenic agents: smart drinks or bitter pills? D. Gingras, A. Renaud, N.
Mousseau, R. B´eliveau, Cancer and Metastasis Reviews 19: 83–86, 2000.
7. New entity
•Water-soluble extract
•Concentrated in biologically-relevant molecules
Effect of Æ-941 on embryonic neovascularization.
Chick embryo
Shark cartilage extracts as anti-angiogenic agents: smart drinks or bitter pills? D. Gingras, A. Renaud, N.
Mousseau, R. B´eliveau, Cancer and Metastasis Reviews 19: 83–86, 2000.
8. Renal and non-small cell
Oncology Neovastat®
lung cancer development
Dermatology Psovascar®
Ophthalmology Neoretna® Discontinued
Rheumatology Arthrovas®
9. October 2002
Orphan drug status in renal cancer (FDA)
September 2003
Phase III study for metastatic renal cancer doesn’t achieve its goal
10. December 2003
Clinical development stopped in renal cancer
February 2006
Clinical development stopped in non-small cells lung cancer
Chemoradiotherapy With or Without AE-941 in Stage III Non–Small Cell Lung Cancer: A Randomized Phase III
Trial, Charles Lu and Al, JNCI, 2010 102 (12)
11. 1990 2002
Aeterna
Laboratories
formation
Zentaris AG
acquisition
12. Degussa AG Asta-Medica GmbH
Zentaris AG
New opportunities
Marketing alliances and strategic partnerships:
•Serono
•Solvay
•Baxter
Aeterna acquires German biopharmaceutical Zentaris from Degussa, PR Newswire
13. New portfolio
•Oncology:
o6 products in clinical trials (phases I to III)
o2 products in preclinical phase
•Endocrinology:
o1 product approved and commercialized
o1 product in clinical trials
o2 products in preclinical phase
14. Atrium Biotechnologies
Inc. acquired Pure
Encapsulations Inc.
March March May
1990 2002
2003 2004 2004
Aeterna GmbH &
Aeterna
Zentaris AG New name:
Laboratories
merger Aeterna Zentaris Inc.
formation
Zentaris AG
acquisition
Aeterna Zentaris, Thomson Reuters Pharma ™company report
15. Atrium Biotechnologies
Inc. acquires
Multichem Inc.
January
2005
Echelon Biosciences
acquisition
Aeterna Zentaris, Thomson Reuters Pharma ™company report
16.
17. Atrium voting shares
distribution
Atrium Biotechnologies
Inc. acquired
Multichem Inc.
January 2006
2005 2007
Echelon Biosciences
acquisition
Aeterna Zentaris, Thomson Reuters Pharma ™company report
18. October 2006: Beginning of Atrium shares distribution
3,485 million voting shares $47 million (24% of
$14,12 each share the company’s ownership)
January 2007: End of Atrium shares distribution
Last 11 million shares
Shareholders would receive 0.2079 of an Atrium share for each
Aeterna share
Aeterna Zentaris, Thomson Reuters Pharma ™company report
19. Atrium voting shares
distribution
Atrium Biotechnologies
Inc. acquired
Multichem Inc.
January 2006 November
2005 2007 2007
Echelon
Echelon Biosciences Biosciences sale
acquisition
20.
21. 80 Aeterna Zentaris Inc.
Canada
10
Aeterna Zentaris GmbH Aeterna Zentaris Inc.
Germany New Jersey, USA
Zentaris IVF GmbH
Germany
Aeterna Zentaris ANNUAL INFORMATION FORM ON FORM 20-F 2010 10
22.
23. Therapeutic areas
Product
development Oncology Endocrinology
Colorectal cancer Adult Growth
Hormone Deficiency
Multiple Myeloma
Own product In vitro fertilization
Endometrial cancer
discovery unit
Ovarian cancer
Prostate cancer
Bladder cancer
25. Approval
EU: 1999
US: 2001
JP: 2006
Marketed
World: Merck Serono > 90
countries
JP: Shionogi
JP: Nippon Kayaku
www.aezsinc.com, Products in the market, Cetrotide®
26. Marketed
In Vitro fertilization
LHRH antagonist
Dose-dependent action
Pr Andrew Schally
Development
Benign Prostatic Hyperplasia
Endometriosis
Uterine myoma
www.aezsinc.com, Products in the market, Cetrotide®
30. FSH or hMG (Gonal-F®)
Stimulates growth of eggs
Cetrotide®
Prevents early
release of hCG
eggs
Induces
maturation of
eggs
Start of Possibility of Eggs nearly Eggs retrieved Embryos transferred
stimulation LH surge mature for fertilization (3 to 5 days after
cycle begin with sperm egg retrieval)
www.aezsinc.com
31. March 2009 Association with Sanofi
Study results: primary endpoints not
December, 7th 2009
matched
End of the association
December, 18th 2009
Discontinuation of Cetrorelix in BHP
80,000
R&D Sales
60,000
-56.2%
Thousands $
40,000
-54.7%
20,000
0
2006 2007 2008 2009 2010
www.aezs.com Financial report 2010 and 2008
33. Oral anticancer
treatment
PI3K (phosphoinositide 3-
kinase) pathway
Alkylphosphocholine
Inhibition of Akt activation
Induction of apoptose
www.aezs.com ANNUAL INFORMATION FORM ON FORM 20-F 2010
35. Phase 3
Multiple Myeloma
Perifosine Bortezomib Dexamethasone
Perifosine Lenalidomid Dexamethasone
September 2009 FDA : Orphan drug
December 2009 FDA : Fast Track designation
March 2010 EMA : Orphan drug
Aeterna Zentaris ANNUAL INFORMATION FORM ON FORM 20-F 2010
36. Phase 3
Colon cancer
Perifosine Capecitabine
April 2010 FDA : Fast Track designation
July 2011 EPO : Patent for the association
Until July 28th, 2023
Aeterna Zentaris ANNUAL INFORMATION FORM ON FORM 20-F 2010
Press release July 12th, 2011
37. Phase 3
Colon cancer
Phase 2 : Time to Progression and Overall Survival
Investor Presentation, February 14th, 2012, www.aezsinc.com
38. Phase 2
Waldenstrom’s Macroglobulinemia
Renal cell carcinoma
Sarcoma
Gliomas
Leukaemia
Non-Small Cells Lung Cancer
+ Radiation therapy Phase 1
Neuroblastoma
Aeterna Zentaris ANNUAL INFORMATION FORM ON FORM 20-F 2010
39. NIH/NCI : Cooperative Research and Development Agreement
May 2000
Access Oncology, Inc./Keryx : Cooperation and license
agreement for the United States, Canada and Mexico
September
2002
Aeterna Zentaris ANNUAL INFORMATION FORM ON FORM 20-F 2010
40. Cooperation and license agreement for the
United States, Canada and Mexico
Free access to all data from Keryx
and its partner’s studies
Milestone payments
Clinical Development
Scale-up royalties to be paid on
future net sales of Perifosine
Aeterna Zentaris ANNUAL INFORMATION FORM ON FORM 20-F 2010
41. NIH/NCI : Cooperative Research and Development Agreement
May 2000
Access Oncology, Inc./Keryx : Cooperation and license
agreement for the United States, Canada and Mexico
September
2002 Handok : Agreement to out-license the rights of Perifosine in
South Korea
April 2009
Yakult : development, manufacture and commercialization of
Perifosine in Japan
March 2011
Aeterna Zentaris ANNUAL INFORMATION FORM ON FORM 20-F 2010
42. Development, manufacture and
commercialization of Perifosine in all human
uses, excluding leishmaniasis in Japan
Initial up-front payment of €6
million ($8.3 million)
Development, Manufacture, Com
Milestone payments : up to €44
mercialization in Japan
million ($60.9 million)
Royalties on future net sales of
Perifosine in the Japanese market
Aeterna Zentaris ANNUAL INFORMATION FORM ON FORM 20-F 2010
43. NIH/NCI : Cooperative Research and Development Agreement
May 2000
Access Oncology, Inc./Keryx : Cooperation and license
agreement for the United States, Canada and Mexico
September
2002 Handok : Agreement to out-license the rights of Perifosine in
South Korea
April 2009
Yakult : development, manufacture and commercialization of
Perifosine in Japan
March 2011
Hikma pharmaceuticals : Commercialization and license
agreement for the MENA region
November
2011
Aeterna Zentaris ANNUAL INFORMATION FORM ON FORM 20-F 2010
Aeterba Zentaris Press Release – November 23rd, 2011
44. Commercialization and license agreement for
the MENA (Middle East and North Africa)
region
Initial up-front payment Leading drug company in the MENA region
Milestone payments : up to $2
million Registration and marketing of
perifosine
Royalties on future net sales of
perifosine in the MENA region
Supply perifosine to Hikma
Pharmaceuticals on a cost-plus-
basis
Aeterba Zentaris Press Release – November 23rd, 2011
49. Cancer Tissue
LHRH receptor (e.g. breast, endometrial, ovarian,
prostate and bladder cancer)
Reproductive Tissue
Hypophysis
Healthy Tissue AEZS-108
Consequence for the cytotoxic agent :
↑ Efficacy ↓ Side-Effects
Investor Presentation, February 14th, 2012, www.aezsinc.com
50. Phase 2
Refractory Ovarian Cancer Positive efficacy and
safety data
Recurrent Endometrial Cancer
Phase 1
Refractory Prostate Cancer Positive efficacy and
safety data
Bladder Cancer
Investor Presentation, February 14th, 2012, www.aezsinc.com
51. Phase 2
Refractory Ovarian Cancer Positive efficacy and
safety data
Recurrent Endometrial Cancer
Phase 1
Refractory Prostate Cancer Positive efficacy and
safety data
Bladder Cancer
Investor Presentation, February 14th, 2012, www.aezsinc.com